OncLive | Rugo Offers Window Into Evolving Views of ER-Positive Disease OncLive So, we followed up with a phase II neoadjuvant trial, Study 22222, of letrozole with or without everolimus, and saw a benefit from the addition of everolimus: a decrease in Ki67 and improved clinical response. Despite having serial tumor samples ... |
